MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
DALLAS, December 8, 2011 /PRNewswire/ –
The report “Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 -
2020)” analyzes and studies the major market drivers, restraints, and opportunities in
geographies such as North America, Europe, and Japan.
Browse market data tables and in-depth TOC on “Chronic Lymphocytic Leukemia
Therapeutics Market in G8 Countries (2010 – 2020)”.
Early buyers will receive 10% customization on reports.
Chronic lymphocytic leukemia is also known as chronic lymphoid leukemia. It can be
described as a slow increase in the number of white blood cells in the blood and the bone
marrow. White blood cells guard the body from infections caused by bacteria. Chronic
lymphocytic leukemia is divided by the type of lymphocyte involved, such as B-cell or
T-cell. Chronic lymphocytic leukemia (CLL) accounts for 35% of the total leukemia.
The chronic lymphocytic leukemia therapeutics market in G8 countries was valued at
$437 million in 2010 and is expected to grow at a CAGR of 13.43% from 2015 to 2020.
Campath accounted for the largest share; i.e. 42.32% of the chronic lymphocytic leukemia
therapeutics market [
] in G8 countries in 2010. However, in 2020, the market is expected to
be dominated by Arzerra drug and GA101/RG7159 molecule, with sales amounting to $603
million and $994 million respectively.
According to WHO, chronic lymphocytic leukemia is expected to be more prominent in the
developed world such as North America and Europe due to genetic factors. The other causes
such as environmental factors and radiation exposure are also the causative of chronic
lymphocytic leukemia. Global incidence of chronic lymphocytic leukemia was 94,960 in 2008
with the developing countries. Total 123,379 new cases were recorded in 2010 with 199,472
and 282,683 as the predicted new cases for 2015 and 2020.
The U.S. dominates the leukemia drug market in North America with 90.19% share;
whereas Germany dominates the market of Europe with 20.49% share.
The major players in the market include F. Hoffmann-La Roche Ltd (Switzerland),
GlaxoSmithKline Pharmaceuticals Limited (U.K.), Biogen Idec (U.S.), Celgene Corporation
(U.S.), Genmab A/S (Denmark), Cephalon Inc. (U.S.), Genentech Inc. (U.S.) and Genzyme
MarketsandMarkets is a global market research and consulting company based in the U.S.
We publish strategically analyzed market research reports and serve as a business
intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and
custom research services. MarketsandMarkets covers thirteen industry verticals; including
advanced materials, automotives and transportation, banking and financial services,
biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial
automation, medical, pharmaceuticals [
semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository. To know more about us and
our reports, please visit our website http://www.marketsandmarkets.com.
Contact: Mr. Rohan 7557 Rambler Road, Suite 727, Dallas, TX 75231 Tel: +1-888-6006-441 Email: email@example.com MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com http://www.sandlerresearch.org http://twitter.com/marketsmarkets